Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...

Pharmacokinetics in Pediatric Patients: Drug Distribution

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...

Chronopharmacokinetics: Time-Dependent Pharmacokinetics

Chronopharmacokinetics: Time-Dependent Pharmacokinetics

Chronopharmacokinetics studies the temporal change in drug absorption and elimination. These changes can be cyclical or non-cyclical. Cyclical changes occur over a regular interval, while non-cyclical changes occur over a longer, irregular period.
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Commentary on "Examining the Evidence Around Acetaminophen and Autism Risk".

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026

Same author

Policy Failure, Not "Hesitancy": Lessons From Recent Measles and Pertussis Outbreaks in the United States.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026

Same author

The semantics of "Doctor": A case of confused identity between nurses and physicians?

Journal of the American Association of Nurse Practitioners·2026

Same author

Evaluation of adalimumab tapering regimens in children and adolescents with juvenile idiopathic arthritis in remission: a simulation study.

Pediatric rheumatology online journal·2026

Same author

Protecting Our Youngest Patients: Why Pediatric Clinical Trials Deserve Safeguards in Federal Restructuring.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2025

Same author

Randomized trial: Peppermint oil (menthol) pharmacokinetics in children and effects on gut motility in children with functional abdominal pain: 540 mg vs. 900 mg dose comparison.

British journal of clinical pharmacology·2025

Search research articles

Related Experiment Video

Updated: May 29, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Developmental pharmacokinetics.

Johannes N van den Anker¹, Matthias Schwab, Gregory L Kearns

¹Division of Pediatric Clinical Pharmacology, Department of Pediatrics, Children's National Medical Center, NW, Washington, DC 20010, USA. jvandena@cnmc.org

Handbook of Experimental Pharmacology

|September 2, 2011

Summary

Understanding how growth affects drug processing (ADME) has advanced, but gaps remain in characterizing enzyme and transporter activity in children. Individualizing drug therapy requires accounting for developmental differences and patient-specific factors.

More Related Videos

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Related Experiment Videos

Last Updated: May 29, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Area of Science:

Pharmacology
Developmental Biology
Clinical Pharmacy

Background:

Significant progress in developmental pharmacokinetics has improved understanding of drug absorption, distribution, metabolism, and excretion (ADME) throughout growth.
However, knowledge gaps persist regarding the ontogeny of drug-metabolizing enzymes, transporters, and other targets in pediatric populations.

Purpose of the Study:

To highlight the need for individualized rational drug therapy in neonates, infants, children, and adolescents.
To address the clinical challenge of accounting for variability in factors influencing pharmacokinetics and pharmacodynamics.
To explore how novel technologies can facilitate developmentally appropriate dosing regimens.

Main Methods:

Review of advances in developmental pharmacokinetics.
Discussion of challenges in pediatric drug therapy.
Exploration of novel technologies including pharmacometrics, pharmacogenomics, and biomarker development.

Main Results:

Enhanced understanding of growth's influence on drug ADME.
Identification of remaining gaps in ontogeny of drug-metabolizing enzymes and transporters.
Recognition of variability from genetic factors, disease phenotypes, and treatments.

Conclusions:

Individualized drug therapy in pediatrics is the goal, requiring consideration of developmental differences.
Integrated approaches using novel technologies are crucial for selecting appropriate pediatric dosing regimens.
Addressing variability in pharmacokinetics and pharmacodynamics is key to optimizing pediatric drug therapy.